Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes

Neurosci Lett. 1999 Jun 25;268(3):115-8. doi: 10.1016/s0304-3940(99)00381-x.

Abstract

Neuropeptide Y (NPY) and different NPY receptor (Y) subtype-selective agonists were tested for their effects on spontaneous epileptiform discharges which developed in rat cortical and hippocampal slices in Mg(2+)-free medium. Epileptiform activity, recorded extracellularly, was attenuated by NPY (0.5-1 microM) in both the frontal cortex and hippocampal CA3/CA1 pyramidal cell layers. In the cortex the Y1/5 selective agonist [Leu31 Pro34] NPY was more effective than the Y2 preferring agonist NPY13-36 and the Y2/5 preferring agonist NPY3-36. The suppression of epileptiform discharges induced by NPY in cortical slices was blocked by the selective Y1 receptor antagonist (R)-N2-(diphenylacetyl)-N-((4-hydroxyphenyl)methyl] argininamide (BIBP 3226). In the hippocampus, NPY13-36 and NPY3-36 were more effective than [Leu31 Pro34] NPY. In conclusion, the antiepileptic activity of NPY is mediated predominantly by the Y1 receptor subtype in the frontal cortex and by Y2 and probably Y5 receptors in the hippocampal CA3/CA1 areas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology*
  • Arginine / analogs & derivatives*
  • Arginine / pharmacology
  • Cerebral Cortex / drug effects*
  • Evoked Potentials / drug effects
  • Hippocampus / drug effects
  • Male
  • Neuropeptide Y / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, Neuropeptide Y / agonists*
  • Receptors, Neuropeptide Y / drug effects*

Substances

  • Anticonvulsants
  • BIBP 3226
  • Neuropeptide Y
  • Receptors, Neuropeptide Y
  • neuropeptide Y-Y1 receptor
  • neuropeptide Y2 receptor
  • Arginine